NDC 0409-7793-13 - Heparin Sodium and Dextrose
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0409-7793
- Requested NDC
- 0409-7793-13
- Package NDCs from labels
- 0409-7793-52, 0409-7793-62, 0409-7793-13, 0409-7793-23
- Manufacturer
- Hospira, Inc.
- Effective date
- 2026-05-25
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Heparin Sodium and Dextrose - Hospira, Inc. | Hospira, Inc. | 2026-05-25 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0409-7793-13 | Heparin Sodium and Dextrose | 100 mL in 1 BAG | INJECTION, SOLUTION | 100 | 35 | |
| 0409-7793-23 | Heparin Sodium and Dextrose | 1 in 1 POUCH | INJECTION, SOLUTION | 1 | 35 | |
| 0409-7793-23 | Heparin Sodium and Dextrose | 24 in 1 CASE | INJECTION, SOLUTION | 24 | 35 | |
| 0409-7793-52 | Heparin Sodium and Dextrose | 250 mL in 1 BAG | INJECTION, SOLUTION | 250 | 35 | |
| 0409-7793-62 | Heparin Sodium and Dextrose | 24 in 1 CASE | INJECTION, SOLUTION | 24 | 35 | |
| 0409-7793-62 | Heparin Sodium and Dextrose | 1 in 1 POUCH | INJECTION, SOLUTION | 1 | 35 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0409-7793-13 | ML - Milliliter | 0409-7793 | ac2d9503-7e67-4930-b366-660c27595af7 | 1 | 2015-04-03 |
| 0409-7793-52 | ML - Milliliter | 0409-7793 | 0dd0f530-99e8-40af-a9ea-875ddb6711b0 | 1 | 2015-04-03 |
| 0409-7793-62 | ML - Milliliter | 0409-7793 | e8f1f19f-b84c-4d76-a9a9-886c4cd7ac1c | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| HEPARIN SODIUM | ACTIVE INGREDIENT | ZZ45AB24CA | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| HEPARIN | ACTIVE MOIETY | T2410KM04A | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| ANHYDROUS CITRIC ACID | INACTIVE INGREDIENT | XF417D3PSL | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| DEXTROSE MONOHYDRATE | INACTIVE INGREDIENT | LX22YL083G | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| SODIUM METABISULFITE | INACTIVE INGREDIENT | 4VON5FNS3C | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 | |
| TRISODIUM CITRATE DIHYDRATE | INACTIVE INGREDIENT | B22547B95K | HEPARIN SODIUM AND DEXTROSE (HEPARIN SODIUM) INJECTION, SOLUTION [HOSPIRA, INC.] | 16 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Heparin Sodium | HEPARIN SODIUM | Fresenius Kabi USA, LLC | ed937dd2-8fab-4875-a1e8-627b71ccb7fb | 2025-11-27 | Warnings, Adverse reactions | ZZ45AB24CA |
| ACD-A | ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A | Fenwal, Inc. | ab19b011-0a51-4f04-9881-d9fc7cae95ae | 2025-11-25 | XF417D3PSL LX22YL083G | |
| Heparin Sodium | HEPARIN SODIUM | Sagent Pharmaceticals | ef309d83-7262-4874-8580-f4ca254f963a | 2025-11-18 | Warnings, Adverse reactions | ZZ45AB24CA |
| Heparin Sodium | HEPARIN SODIUM | Sagent Pharmaceuticals | 6d5eae7d-a5f6-411c-b589-3e5f7eecc875 | 2025-11-18 | Warnings, Adverse reactions | ZZ45AB24CA |
| Heparin Sodium | HEPARIN SODIUM | Sagent Pharmaceuticals | feec2820-502f-4a97-84c9-f173729c51d3 | 2025-11-18 | Warnings, Adverse reactions | ZZ45AB24CA |
| Heparin Sodium | HEPARIN SODIUM | Sagent Pharmaceuticals | 8ebe4b4d-cb28-47e8-9598-6105d250b3d2 | 2025-11-18 | Warnings, Adverse reactions | ZZ45AB24CA |
| Alka-Seltzer Original | ANHYDROUS CITRIC ACID, ASPIRIN, AND SODIUM BICARBONATE | R J General Corporation | dbb0d067-71f0-45e4-bc98-548cf4a90b3a | 2025-11-17 | Warnings | XF417D3PSL |
| Dextrose in Lactated Ringers | DEXTROSE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, AND CALCIUM CHLORIDE | B. Braun Medical Inc. | 190da07e-a616-46e6-b4e5-1c0ba39306e5 | 2025-11-05 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | ICU Medical, Inc. | 8b25b7e0-703e-4b43-a4eb-52863511602d | 2025-11-02 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, AND POTASSIUM CHLORIDE | ICU Medical Inc. | d8ee14e9-6733-4813-9f21-2b043a5f7188 | 2025-11-02 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose and Sodium Chloride | DEXTROSE MONOHYDRATE AND SODIUM CHLORIDE | ICU Medical Inc. | 4555b1bf-6d97-4798-a63d-6d34291c85ce | 2025-11-02 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE | ICU Medical Inc. | b5cb7a5a-bbe8-4217-a82e-da818f7771c9 | 2025-11-02 | Warnings, Adverse reactions | LX22YL083G |
| Lactated Ringers and Dextrose | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, AND DEXTROSE MONOHYDRATE | ICU Medical Inc. | d310d170-5eeb-471b-af1a-0e845001d21d | 2025-11-02 | Warnings, Adverse reactions | LX22YL083G |
| Dextrose | DEXTROSE MONOHYDRATE | ICU Medical, Inc. | cb578dba-094c-4787-951d-763d12fd06e1 | 2025-11-01 | Warnings, Adverse reactions | LX22YL083G |
| Heparin Sodium | HEPARIN SODIUM | Henry Schein, Inc. | 3a998729-c912-4e21-8e49-d1e72ba6fe9e | 2025-10-31 | Warnings, Adverse reactions | ZZ45AB24CA |
| Potassium Chloride in Lactated Ringers and Dextrose | POTASSIUM CHLORIDE, SODIUM CHLORIDE, CALCIUM CHLORIDE, SODIUM LACTATE, AND DEXTROSE MONOHYDRATE | ICU Medical Inc. | 237b39fa-916e-4a54-99c8-4ae9ad54f056 | 2025-10-30 | Warnings, Adverse reactions | LX22YL083G |
| Normosol-R and Dextrose | DEXTROSE, SODIUM CHLORIDE, SODIUM ACETATE ANHYDROUS, SODIUM GLUCONATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | ICU Medical Inc. | ead1fca3-eff4-478f-8a8f-67510f80151a | 2025-10-30 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Dextrose | DEXTROSE MONOHYDRATE AND POTASSIUM CHLORIDE INJECTION, SOLUTION | ICU Medical Inc. | 02d694b5-3600-4d55-bd5c-924abaec5315 | 2025-10-30 | Warnings, Adverse reactions | LX22YL083G |
| Ionosol MB and Dextrose | DEXTROSE MONOHYDRATE, SODIUM LACTATE, POTASSIUM CHLORIDE, MAGNESIUM CHLORIDE, POTASSIUM PHOSPHATE, MONOBASIC, AND SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE | ICU Medical Inc. | 1b457b1d-0e80-4578-ba6f-dedf513fc962 | 2025-10-30 | Warnings, Adverse reactions | LX22YL083G |
| Potassium Chloride in Lactated Ringers and Dextrose | DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE | Baxter Healthcare Corporation | 05f326e6-10e4-4ceb-8a23-f53c592f00b8 | 2025-10-29 | Warnings, Adverse reactions | LX22YL083G |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.